Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1). The trial is an open-label Phase II study designed to...
A cure for the confounding condition multiple myeloma may have been found.
A single antibody could be the key to treating multiple myeloma, or cancer of the blood, currently without cure or long-term treatment.
“We tested the antibody in various ways, including on tumour cells from myeloma...
Multiple myeloma is a type of leukaemia which affects B lymphocytes. There have been some indications that exposure to pesticides or chlorinated solvents increases the risk of developing this cancer. New research published in Biomed Central's open access journal Journal of Occupational Medicine...
A three-drug treatment for the blood cancer multiple myeloma provided rapid, deep and potentially durable responses, researchers report online in Blood, the Journal of the American Society of Hematology, and at the American Society of Clinical Oncology's Annual Meeting in Chicago, IL, USA. The...
Low dose whole body CT is nearly four times better than radiographic skeletal survey, the standard of care in the U.S., for determining the extent of disease in patients with multiple myeloma, a new study shows. The study, conducted at the University of Maryland in Baltimore, included 51...
Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France. The phase III study evaluated the benefits of continuous, or maintenance, treatment with...
Abbott (NYSE: ABT) and Bristol-Myers Squibb Company (NYSE: BMY) announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and...
Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology (ASH), to be held on December 4-7 in Orlando, FL, the company announced. Kenna Anderes, VP Cancer Biology...
Zoledronic acid improves survival in multiple myeloma patients versus the UK and European standard treatment of clodronic acid (sodium clodronate) in patients with multiple myeloma. Since overall survival in patients given zoledronic acid improved independently of prevention of skeletal-related...
Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS™. The official launch of MyPRS™ will take place...
In draft guidance published today (26 August 2010) NICE has recommended two treatments for multiple myeloma. Thalidomide (Thalidomide, Celgene) in combination with an alkylating agent and a corticosteroid is recommended for the first-line treatment of multiple myeloma in people for whom...
The International Myeloma Foundation (IMF), the oldest and largest foundation dedicated to improving the life and care of myeloma patients, today said this year's ASCO cancer conference could change the way patients are treated. The data favor fewer stem cell transplants and increased use of...
The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported at the 51st Annual Meeting of the American Society of Hematology. The updated data...